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Abstract
Background: Based on its role in angiogenesis and apoptosis, the inhibition of NFκB activity is
considered an effective treatment for cancer, hampered by the lack of selective and safe inhibitors.
We recently demonstrated that the RH domain of GRK5 (GRK5-RH) inhibits NFκB, thus we
evaluated its effects on cancer growth.
Methods: The role of GRK5-RH on tumor growth was assessed in a human cancer cell line (KAT-
4). RH overexpression was induced by adenovirus mediated gene transfer; alternatively we
administered a synthetic protein reproducing the RH domain of GRK5 (TAT-RH), actively
transported into the cells.
Results: In vitro, adenovirus mediated GRK5-RH overexpression (AdGRK5-NT) in human tumor
cells (KAT-4) induces IκB accumulation and inhibits NFκB transcriptional activity leading to
apoptotic events. In BALB/c nude mice harboring KAT-4 induced neoplasias, intra-tumor delivery
of AdGRK5-NT reduces in a dose-dependent fashion tumor growth, with the highest doses
completely inhibiting it. This phenomenon is paralleled by a decrease of NFκB activity, an increase
of IκB levels and apoptotic events. To move towards a pharmacological setup, we synthesized the
TAT-RH protein. In cultured KAT-4 cells, different dosages of TAT-RH reduced cell survival and
increased apoptosis. In BALB/c mice, the anti-proliferative effects of TAT-RH appear to be dose-
dependent and highest dose completely inhibits tumor growth.
Conclusion: Our data suggest that GRK5-RH inhibition of NFκB is a novel and effective anti-
tumoral strategy and TAT-RH could be an useful tool in the fighting of cancer.
Background
NFκB is a dimeric, ubiquitous transcription factor
involved in cellular responses to stimuli such as stress,
cytokines, free radicals, ultraviolet irradiation, oxidized
LDL, and bacterial or viral antigens [1-5]. In basal condi-
tions, NFκB dimers are sequestered in the cytoplasm by a
family of inhibitors, called IκBs, that bind NFκB by means
of ankyrin repeat domains masking its nuclear localiza-
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tion signals (NLS); such interaction blocks NFκB in an
inactive form in the cytoplasm [6]. Activation of NFκB is
initiated by the signal-induced phosphorylation of IκB
proteins by IκB kinase (IKK), thus inducing IκB ubiquiti-
nation and degradation by the proteasome. At this time,
NFκB is active and stably localized within the nucleus
where it induces the expression of specific genes. The acti-
vation of these genes by NFκB then leads to inflamma-
tion, immune response, cell survival, or cellular
proliferation depending on cell type. The pathogenetic
role of NFκB has been clarified in many diseases [7-9],
such as type II diabetes and insulin-resistance [10,11]; car-
diac hypertrophy [12]; atherosclerosis [13]; chronic heart
failure [14]; cancer and angiogenesis [15].
There are many evidences about the role of NFκB in can-
cer. Indeed, Hanahan and Weinberg identified the six
hallmarks that characterized tumor cells (Self-Sufficiency
in Growth Signals, Insensitivity to Anti-growth Signals,
Evading Apoptosis, Limitless Replicative Potential Sus-
tained Angiogenesis, Tissue Invasion and Metastasis)
[16,17] and most of the genes that regulate such effects are
under the transcriptional control of NFκB. Moreover,
NFκB transcription activity is constitutively increased in
many tumors like melanoma [18,19], thyroid [20,21] and
colon [22] carcinoma. The mechanisms determining per-
sistent and de-regulated NFκB activity in cancer cells are
not well understood but a major role is probably played
by the cellular concentration of the inhibitory protein IκB.
In particular, the constitutive activation of NFκB in solid
tumors has been mainly attributed to decreased IκB levels
due to defective IκBα activity, constitutive IKK activity,
enhanced proteasome activity, etc.
To date, different approaches have been developed to
block NFκB in several conditions. A successful one is
using a proteasome inhibitor, PS-341, to treat patients
with refractory or resistant multiple myeloma [23]. A pro-
tein that disrupts the association of the IKK complex is
used to prevent inflammatory bone destruction [24]. The
inhibition of IκBα phosphorylation by the Bay 11-7082
compound, has been successfully used to prevent tumor
growth and leukemic infiltration in a mouse model of
adult T cell leukemia [25]. Furthermore, inhibition of
NFκB activation by expression of a mutant IκBα, which is
resistant to phosphorylation and degradation, increased
NFκB dependent apoptosis to stimuli such as TNFα
[26,27]. All these approaches open new fields for the
management of NFκB-associated diseases like cancer.
G protein coupled receptor (GPCR) kinases (GRKs) regu-
lates GPCRs signaling by inducing receptor desensitiza-
tion. Recent findings unveil new cellular function for
these kinases. Indeed, we have recently demonstrated that
GRK5 regulates the activity of the transcription factor
NFκB [28]. In particular, in endothelial cells GRK5 is able
to bind the inhibitory protein of NFκB, IκBα, by means of
the RH domain (GRK5-RH) and stabilize the complex
IκBα/NFκB in the nucleus, thus inhibiting NFκB tran-
scriptional activity [28]. Indeed, RH overexpression,
which causes GRK5-IκBα interaction, inhibits the tran-
scriptional activity and DNA binding of NFκB both in
basal condition and after stimulation with LPS.
Given the notion that the modulation of NFκB transcrip-
tional activity is an effective therapeutic strategy for can-
cer, we hypothesized that RH, being a potent inhibitor of
NFκB, could reveal therapeutic potentialities in oncology.
We therefore tested in a human tumor cell line, KAT-4, the
effects of GRK5-RH on cell growth either in cultured cells
or in tumors in BALB/c nude mice, grown after subcutane-
ous injection of KAT-4 cells.
Materials and methods
Cell culture
Human tumor cells (KAT-4) were a kind gift of Dr. Madd-
alena Illario (Federico II University, Dept. of Cellular and
Molecular Pathology). This cell line has been recently
authenticated by short tandem repeat (STR) profiling
which demonstrated, despite the widespread knowledge,
that KAT-4 are not of thyroid cancer origin but share the
same STR profile with the HT-29 colon cancer cell line
[29]. Cells were cultured in Dulbecco's minimal essential
medium (DMEM) supplemented with 10% foetal bovine
serum (FBS) at 37°C in 95% air-5%CO2.
Plasmid constructs
In order to synthesize a protein reproducing the RH
domain of GRK5, engineered to be actively transported
into the cells by means of TAT sequence, we designed the
TAT-RH plasmid, using pcDNA3.1-GRK5-RH [28] as tem-
plate to amplify RH sequence. The primers were designed
with the addition of NCO I and KPN I restriction sites
sequences:
5'CCCCCATGGCCCGAGATTACTGCAGTTTA3' and
3'ATAAAACTAGCGAAAGAGATCCCATGGGGG5';
Amplified sequences were purified by gel extraction kit
(Invitrogen) and cloned into pTAT-HA vector a kind gift
of Dr. Steven Dowdy (Washington University School of
Medicine) [30] by means of T4 DNA ligase (Promega).
The right frame and orientation were confirmed by restric-
tion analysis and DNA sequencing (Avant 3100, Applied
Biosystem). pTAT-HA vector comprises the 11 aminoacid
TAT domain, that is the minimum sequence of HIV TAT
able to transduce into cells, and histidine and HA as tags.
Production of adenoviral vectors
The adenoviral construct GRK5-NT (AdGRK5-NT) used
for gene transfer in vivo has been previously described
[28]. AdGRK5-NT comprises the N terminal and RHMolecular Cancer 2009, 8:97 http://www.molecular-cancer.com/content/8/1/97
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domains of GRK5 conjugate to Green Fluorescen Protein
gene (GFP) under the CMV promoter.
For Lac-z adenoviral construct, we subcloned Lac-Z gene,
excised by digestion from pcDNA 3.1/Lac-Z (Invitrogen),
into the AscI site of the pShuttle-linker plasmid, and the
resulting plasmid was used to generate the first generation
of adenoviruses (AdLac-Z).
First-generation of adenoviral vectors AdGRK5-NT and
AdLac-Z was amplified in 293N3S cells in monolayer for
small-scale amplification and in suspension for large scale
amplification. Virus production was performed as fol-
lows: 3 liters of 293N3S cells at a concentration of 3-4 ×
105 cells/ml were harvested by centrifugation and resus-
pended in 5% of the volume of conditioned medium and
then infected with all the crude lysate obtained from the
infection of two 150-mm dishes. Virus adsorption was
performed at 37°C on a magnetic stir plate for 2 hours;
after this step, medium (25% conditioned and 75% fresh
Joklik's MEM supplemented with 5% FBS) was added to a
final volume of 2 liters. Infected cells were harvested after
48 hours, lysed and resuspended in TM solution (10 mM
Tris-HCl pH 8.0, 2 mM MgCl2). After three freeze-thaw
cycles cells were incubated in 2 M MgCl2 in presence of
DNase (10 mg/ml) for 1 hour at 37°C. After DNAase
incubation, cellular debris were eliminated by centrifuga-
tion at 3500 rpm for 15 minutes and the remaining lysate
was subjected to ultracentrifugation on a continuous
CsCl2 gradient at 35,000 rpm for 2 hours at 4°C. The
upper band, which contains empty particles, was elimi-
nated and a second ultracentrifugation on a continuous
CsCl gradient (35,000 rpm for 18 hr at 4°C) was per-
formed. The harvested vector was dialyzed twice against
TM with 4% sucrose and stored at -80°C until use. Vector
concentration (particle number) was determined by UV
spectrophotometric analysis at 260 nm.
Protein synthesis and purification
TAT and TAT-RH plasmids were transformed into a BL21
(DE3) pLysS (Invitrogen) bacterial strain. 2 L of Luria
Broth (LB) culture was grown overnight and then Isopro-
pylthiogalactoside (IPTG, 100 μM, 3 hrs) was added to
induce protein expression. For protein purification we
used denaturing conditions to recover all the recombinant
proteins from bacterial inclusion bodies (Lysis buffer: 8 M
Urea, 100 mM NaCl, 20 mM Hepes pH 8). Ni-NTA col-
umns (GE Healthcare) were used for protein purification.
Columns were pre-equilibrated with 10 mM imidazole;
lysates were clarified by sonication and applied to the col-
umns. After extensive washing with lysis buffer plus 20
mM imidazole, recombinant protein were eluted with
increasing amounts of imidazole (100, 200 and 500 mM).
Protein refolding was realized by buffer exchanging into
Tris 1 M pH 7.5 using Amicon Ultra-4 Centrifugal Filters
(Millipore). The recombinant protein TAT-RH was added
to the culture medium in KAT-4 cells for the in vitro study
and injected intra-tumor for the in vivo study. TAT protein
was used as control.
Nuclear extracts preparation, Immunoprecipitation and 
western blot and Apoptosis analysis
The experiments were performed as previously described
[28].
Luciferase assay
Cells were transfected with plasmid expression vectors
containing the luciferase reporter gene linked to five
repeats of a NFκB binding site (κB-Luc) or β-galactosidase
(β-Gal) and infected with AdGRK5-NT. Transient transfec-
tion was performed using the Lipofectamine 2000 (Invit-
rogen) according to manufacturer's instruction. Lysates
were analysed using the luciferase assay system with
reporter lysis buffer from Promega and measured in a β-
counter. Relative luciferase activity was normalized
against the co-expressed β-galactosidase activity to over-
come variations in transfection efficiency between sam-
ples.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed using nuclear extracts. Double
stranded NFκB oligonucleotide (5' AGTTGAGGGGACTT-
TCCCAGGC 3') was end-labelled using [32P]-γ ATP (GE
Healthcare) and T4 polynucleotide kinase (Roche). Sam-
ples were subject to electrophoresis in 8% non denaturing
polyacrilamide gels with 0.5% TBE buffer (0,09 M Tris,
0,09 M boric acid, 0,02 M EDTA). Digitalized gels autora-
diographies were then quantified (Image Quant).
In vivo Study Design
Experiments were carried out, in accordance to NIH
guidelines for Animal Investigation, in 6-weeks-old BALB/
c immunoincompetent nude mice (Charles River), which
had access to food and water ad libitum. For tumor forma-
tion, a suspension containing 2 × 106 KAT-4 cells in 200
μl of DMEM were injected subcutaneously in the dorsal
side of nude mice. Animals were anesthetized using iso-
fluorane 2%. We used mice that developed tumors of
approximately 6 mm in 2 weeks. Mice were divided into 9
groups (5 mice/group) and administered twice a week for
17 days (AdGRK5-NT) or 4 weeks (TAT-RH) with intra-
tumor injections of the specific treatment.
In particular, two groups received AdGRK5-NT at either
low (108 pfu/ml) or high dosage (1011 pfu/ml) while
another group received the higher dose of AdLACZ and
was used as negative control. Three more groups of mice
were treated with TAT-RH protein at the dosage of 8, 12 or
16 mg/Kg. These mice were compared to two control
groups treated with either saline solution or the pTAT-HAMolecular Cancer 2009, 8:97 http://www.molecular-cancer.com/content/8/1/97
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protein lacking the RH sequence. Tumor growth was
measured by caliper twice a week and by Ultrasound
(VeVo 770, Visualsonics) once a week. At the end of the
treatment, mice were sacrificed by cervical dislocation and
tumors processed for biochemical or histological analysis.
All in vivo experimental protocols were approved by the
Federico II University Ethical Committed for Animal
Studies.
Real Time PCR
Total RNA was isolated using Trizol reagent (Invitrogen)
and cDNA was synthetized by means of Thermo-Script
RT-PCR System (Invitrogen), following the manufacturer
instruction. After reverse transcription reaction, real-time
quantitative polymerase chain reaction (PCR) was per-
formed with the SYBR Green real time PCR master mix kit
(Applied Biosystems).
The reaction was visualized by SYBR Green Analysis
(Applied Biosystem) on StepOne instrument (Applied
Biosystem).
Primers for cytokines gene analysis were as follows:
TNFα: forward, 5'CCAGGAGAAAGTCAGCCTCCT3';
reverse, 5'CGATAAAGGGGTCAGAGTAAT3'; VEGF: for-
ward, 5'CAGGCTGTCGTAACGATGAA3', reverse
5'TTTCTTGCGCTTTCGTTTTT3', GAPDH: forward,
5'AGTATGTCGTGGAGTCTACT3', reverse 5'TGTGG
TCATGAGCCCTTCCAC3'.
All values obtained were normalized to the values
obtained with the GAPDH primers. The results are
expressed as the relative integrated intensity.
Histology and Immunocytochemistry
Paraffin embedded sections were processed for the triple
layered immunocytochemical peroxidase anti-peroxidase
(PAP) method. PCNA (Cell signaling), Cleaved caspase 3
(Cell signalling) and Lectin (Sigma) antiserum were used
to analyze cell proliferation, death and neo-angiogenesis,
respectively. The peroxidase was revealed in presence of
0,03% hydrogen peroxide and of an electron donor, 2,5%
diaminobenzidine, which becomes visible as a brown pre-
cipitate. For negative controls, the primary antiserum was
omitted. Sections were then viewed with an Eclipse E1000
Fluorescence Microscope (Nikon) and acquired using
Sigma Scan Pro software (Jandel). For X-GAL staining and
GFP visualization, cryostat sections were incubated with
β-GAL solution (PBS, 0.02 mM K3Fe(CN)6, 0.02 mM
K4Fe(CN)6, 0.02 mM MgCl2, 0.002% NP40, 0.05 mg/ml
X-GAL stain) for 90 min at 37°C and counterstained with
Eosin. Adobe Photoshop was used for final assembly of
the images.
Statistical Analysis
All values are presented as mean ± SEM. Two-way ANOVA
was performed to compare the different parameters
among the different groups. A significance level of P <
0.05 was assumed for all statistical evaluations. Statistics
were computed with GraphPad Prism Software (San
Diego, California).
Results
1) Adenoviral mediated overexpression of GRK5-RH
a) Cell studies
As previously demonstrated in endothelial cells [28], also
in KAT-4 cells AdGRK5NT causes transgene expression
that can be visualized through GFP fluorescence at green
light (Figure 1A). This maneuver leads to IκBα accumula-
tion in whole cell extracts (Figure 1A). In cancer cells
NFκB activity inhibits apoptotic events. Thus, we assessed
apoptosis in KAT-4 cells with adenoviral mediated overex-
pression of GRK5-RH. This maneuver increases cleaved
caspase 3 levels compared to controls (Figure 1B). Similar
results were achieved by Annexin V cell staining (Figure
1C). These responses associate with inhibition of NFκB
activity, assessed by luciferase assay (Figure 1D). These
data demonstrate that GRK5-RH inhibits NFκB transcrip-
tional activity and biological effects also in cancer cells.
b) BALB/c nude mice tumors
In nude mice, the injection of 2 × 106 KAT-4 cells in the
dorsal lateral region results in the development of a ~6
mm diameter tumor in 2 weeks, in about 70% of mice.
Tumors were treated with different doses of AdGRK5-NT.
One high dose of AdLac-Z was used as control.
Low doses of AdGRK5-NT retard tumor growth compared
to controls (Figure 2A). High doses are more effective,
inducing a complete inhibition of tumor growth (Figures
2A).
After 17 days of treatment, mice were sacrificed and
tumors were taken for biochemical and histological anal-
ysis. Expression of AdGRK5-NT transgene is found by GFP
fluorescence in the majority of cells within tumor when
observed under green light (Figure 2B). In control tumors,
LAC-Z expression is confirmed by blue X-GAL staining at
direct light (Figure 2B). In order to evaluate the effect of
GRK5-RH, we performed a western blot in homogenized
tumors to analyze IκBα expression and apoptosis. Figure
2C shows that adenoviral mediated overexpression of
GRK5-RH induces an increase of IκBα and cleaved caspase
3 levels in treated tumors compared to controls. NFκB
also controls tumor angiogenesis. Therefore, we evaluated
VEGF expression and found it significantly decreased in
treated tumors compared to controls (Figure 2C). Results
suggest that adenoviral mediated GRK5-RH expressionMolecular Cancer 2009, 8:97 http://www.molecular-cancer.com/content/8/1/97
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inhibits NFκB activity in tumor cells. Indeed, EMSA anal-
ysis of tumors confirms NFκB inhibition: less NFκB is
bound to genomic DNA in treated tumors compared to
controls (Figure 2D).
2) Effects of administration of TAT-RH protein
a) Cell studies
To close up to a more pharmacological tool, we designed
(Figure 3A) a protein (TAT-RH) reproducing the RH
domain of GRK5, engineered to be actively transported
into the cells through the retroviral TAT sequence and
tested its anti-cancer property. Synthesis of the recom-
binant TAT-RH was performed in bacteria and column
purification was confirmed by SDS-PAGE (Figure 3B).
To verify the ability of TAT-RH protein to translocate into
cells autonomously, we added the protein into the
medium of cultured KAT-4 cells for 1 hour and verified its
internalization by means of precipitation and western
blot from cell lysates (Figure 4A). To verify the biological
effect of TAT-RH, we evaluated IκBα and cleaved caspase
3 levels. TAT-RH increases both IκBα and cleaved caspase
3 levels (Figure 4B), thus confirming that our protein also
in these cells causes apoptosis. Apoptosis was also
assessed by Annexin V staining. Using different doses of
TAT-RH, we found that the minimum amount of protein
needed to exert biological functions is 0.5 μg/ml
(Figure 5).
Effects of GRK5-RH in vitro in KAT-4 cells overexpressed by adenovirus mediated gene transfer Figure 1
Effects of GRK5-RH in vitro in KAT-4 cells overexpressed by adenovirus mediated gene transfer. A) IκBα and 
GRK5-RH levels were analyzed in whole extracts by western blot, in KAT-4 overexpressing GRK5-RH by means of adenovirus 
mediated gene transfer. GRK5-RH increases IκBα levels. GRK5-RH expression was visualized by WB using anti-GFP antibody. 
B) To evaluate GRK5-RH effect on apoptosis, we analyzed the cleavage of caspase 3 by WB. The overexpression of GRK5-RH 
increases cleaved caspase 3 levels, suggesting that GRK5-RH causes an increase of apoptotic responses. C) This result was 
confirmed by Annexin V staining in fluorescence. GRK5-RH overexpression causes apoptosis as shown by Annexin-V staining 
compared to live cells (green = Annexin V; blue = nuclei) D) We evaluated GRK5 effects on NFκB activity by luciferase assay, 
in KAT-4 overexpressing GRK5-RH. Cells were transfected with plasmids coding for a κB-luciferase reporter (κB-Luc) and β-
galactosidase (β-Gal) and lysates were analyzed by luciferase assay system (Promega). GRK5-RH inhibits NFκB transcriptional 
activity (*p < 0.05 vs control).Molecular Cancer 2009, 8:97 http://www.molecular-cancer.com/content/8/1/97
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Effects of GRK5-RH in vivo on tumor growth and biochemical analysis: treatment with adenovirus Figure 2
Effects of GRK5-RH in vivo on tumor growth and biochemical analysis: treatment with adenovirus. A) To vali-
date our in vitro results, we studied the effects of adenoviral mediated overexpression of GRK5-RH in a cancer model in vivo. 
Tumor growth was measured twice a week by a caliper during all the treatment long (17 days of treatment). Low doses (108 
pfu/ml in 200 ul) of AdGRK5-NT retard tumor growth compared to controls. High doses (1011 pfu/ml in 200 μl) are more 
effective, inducing a complete inhibition of tumor growth. Figure also shows a representative image of tumors at the end of the 
treatment. B) 17 days from starting treatment, mice were sacrified and tumors were taken for histological analysis. To ascer-
tain GRK5-RH expression, cryostat sections were analyzed by direct observation of the green light at the fluorescence micro-
scope. LAC-Z expression in control tumors was evaluated by X-GAL staining at direct light (blue staining indicates LAC-Z 
expression; eosin was used for counterstaining in red). C) Tumors were homogenized to analyze IκBα levels, VEGF produc-
tion and apoptosis. Adenoviral mediated overexpression of GRK5-RH induces an increase of IκBα and cleaved caspase 3 levels 
and a reduction of VEGF expression in treated tumors compared to controls treated with AdLac-Z. D) Nuclear extracts from 
tumors were analyzed by EMSA. AdGRK5-NT inhibits NFκB activity compared to controls. Lane 1 = probe alone; Lane 2 = 
empty; Lane 3-4 = AdLac-Z different treated tumors; Lane 5-6 = AdGRK5-NT treated tumors.Molecular Cancer 2009, 8:97 http://www.molecular-cancer.com/content/8/1/97
Page 7 of 12
(page number not for citation purposes)
b) BALB/c nude mice tumors
We first tested the safety of in vivo administration of our
protein in healthy nude mice. There were no significant
changes in body weight among treated and control groups
of mice indicating no toxicity of the treatment (Table 1).
Internal organs (liver, lung, kidney) were then analyzed
by histology. No morphological differences were found in
treated mice compared to controls (data not shown). The
effect of our protein on tumor growth appears to be dose-
dependent. Indeed, high doses (16 mg/kg) lead to regres-
sion of tumors, intermediate doses (12 mg/kg) are able to
completely inhibit tumor growth, since tumors maintain
the same size of starting treatment, and low doses (8 mg/
kg) can delay tumor growth (Figure 6A). As a control, we
treated a group of 5 mice with the synthetic protein TAT
lacking the GRK5-RH domain and a group with saline.
Tumor was equal in mice treated with saline solution and
those treated with TAT (Figure 6A).
The effects of TAT-RH treatment on IκBα levels, apoptosis
and angiogenesis, were assessed in control, 12 mg/kg and
8 mg/kg treated mice since at higher doses (16 mg/kg) of
protein the tumor had a too small size for biochemical
assessments. Figure 6B shows that TAT-RH treatment
leads to a dose-dependent increase of IκBα and cleaved
caspase 3 and a reduction of VEGF levels. Such effects is
associated with NFκB activity inhibition, as evaluated by
EMSA (Figure 6C).
To measure angiogenesis in these tumors, lectin staining
was used to visualize microvessels. Figure 7A shows that
TAT-RH protein design and purification Figure 3
TAT-RH protein design and purification. A) We syn-
thesized and purified a protein reproducing the RH domain 
of GRK5, TAT-RH. To this aim, RH gene was cloned into the 
pTAT-HA vector comprising the 11 aminoacid TAT domain, 
that is the minimum sequence of HIV TAT able to transduce 
into cells, and histidine and HA as N-terminal tags. B) The 
purified protein (~24 kDa) was visualized by electrophoretic 
analysis of samples from all steps of the purification process 
and gel staining. M = marker; Lane 1 = start; Lanes 2-3 = flow 
through; Lanes 4-6 = wash; Lanes 7-9 = imidazole.
Biological effects of TAT-RH in KAT-4 cells Figure 4
Biological effects of TAT-RH in KAT-4 cells. A) To 
evaluate the ability of the recombinant protein to autono-
mously enter into cells, we added TAT-RH (0,5 μg/ml) for 1 
hour to culture medium and prepared cell lysates after three 
washes with saline buffer. We then evaluated the presence of 
TAT-RH in cell lysates by means of histidine precipitation and 
HA analysis by western blot. The purified protein was used 
as positive control. B) To verify the biological effect of TAT-
RH, we evaluated IκBα and cleaved caspase 3 levels which 
were both increased by treatment. Actin was used as con-
trol. C) Apoptosis was also analized by Annexin V staining. 
TAT-RH increases Annexin V staining compared to controls 
(green = Annexin V; blue = nuclei).Molecular Cancer 2009, 8:97 http://www.molecular-cancer.com/content/8/1/97
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TAT-RH reduces the formation of tumor vasculature. Cell
death and proliferation were evaluated by analysis of
cleaved caspase 3 and PCNA levels. TAT-RH treated
tumors show increased cleaved caspase 3 levels (Figure
7B) and reduced cell proliferation (Figure 7C). We also
evaluated IκBα subcellular localization by immunohisto-
chemistry. As previously demonstrated in endothelial
cells, IκBα mainly localizes in the cytosol in control
tumors while TAT-RH treatment causes its nuclear accu-
mulation (Figure 7D).
VEGF and TNFα expression was evaluated by Real Time
PCR to assess the ability of TAT-RH to inhibit NFκB-
dependent gene expression in cancer cells. Figure 8 shows
that at 2 weeks from starting treatment both VEGF and
TNFα expression is strongly inhibited and prolonged
treatments (4 weeks) increase such effect.
Discussion
The major finding of our manuscript is that GRK5-RH
causes NFκB inhibition, through a novel mechanism of
IκB stabilization, and leads to inhibition of growth and
regression of size of tumors both in vitro and in vivo. We
provide evidence using two sets of experiment: the first
set, gathered through the overexpression of GRK5-RH by
AdGRK5-RH, provides the proof of concept that GRK5-
RH is able to inhibit cancer growth. It also represents the
background for the synthesis and administration of a
recombinant protein that resembles the inhibitory fea-
tures of GRK5-RH, which was used in the second set of
data, showing that TAT-RH can be used to obtain pharma-
cological inhibition of tumor growth.
It is known that a sustained, constitutive activation of
NFκB contributes to malignant progression and therapeu-
tic resistance in most of the major forms of human cancer,
such as human lymphomas [31], carcinomas of the breast
[32], prostate [33], lung [34], colon [22], pancreas [35],
thyroid [21], head and neck [36] and cervix [37]. Thus, the
modulation of NFκB activity represents an useful thera-
peutic strategy for cancer, since NFκB inhibition promotes
apoptotic events induced by chemotherapy, reduces the
high proliferative rate that characterizes tumor cells and
inhibits metastasis [13]. We have recently demonstrated
that the RH domain of GRK5 is an effective inhibitor of
NFκB transcriptional activity in endothelial cells with
implications in wound healing and tissue regeneration. In
the present study we evaluated the effects of GRK5-RH in
cancer. Our study was performed on an aggressive human
carcinoma, the KAT-4 cell line. This tumor shows high
proliferative rates and is NFkB sensitive [38]. Several strat-
egies have been developed for blocking NFκB in tumors
that include the inhibition of NFκB signaling pathway by
proteasome inhibitors, IKK inhibitors, antioxidants or
recombinant adenovirus-mediated overexpression of the
IκBα gene, interfering with NFκB mRNA using specific
anti-sense oligonucleotide [39-41]. We synthesized a pro-
tein reproducing the RH domain of GRK5, engineered to
be actively transported into the cells by means of TAT
domain without the support of other vehicles and tested
its anti-cancer property. This approach has been already
successfully used for protein transport in the treatment of
several mouse model of cancer, inflammation and other
diseases [42,43]. Our data suggest that TAT-RH protein
enters into tumor cells, inhibits NFκB transcription activ-
ity and induces apoptosis, reduces tumor angiogenesis,
Apoptosis analysis by Annexin V staining in TAT-RH treated  cells Figure 5
Apoptosis analysis by Annexin V staining in TAT-RH 
treated cells. To verify the effect of TAT-RH on NFκB-
dependent apoptosis, we performed an Annexin V staining 
analysis in KAT-4 cells using different doses of TAT-RH to 
verify the minimum amount of protein needed to exert bio-
logical functions (green = Annexin V; blue = nuclei).
Table 1: Mice body weight during TAT-RH treatment (gr)
Days of tretament CTRL TAT RH 16 mg/kg
0 26,2 ± 0,10 25,6 ± 0,28
7 25,8 ± 0,41 24,7 ± 0,23
17 22,7 ± 0,32 24,0 ± 0,35
28 22,7 ± 0,32 23,4 ± 0,35
We tested the safety of intraperitoneal administration of our protein 
in healthy nude mice. There were no significant changes in body 
weight among treated and control groups of mice indicating low 
toxicity of the treatment. Data are expressed as mean ± SE.Molecular Cancer 2009, 8:97 http://www.molecular-cancer.com/content/8/1/97
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Effects of TAT-RH in vivo on tumor growth and biochemical analysis Figure 6
Effects of TAT-RH in vivo on tumor growth and biochemical analysis. A) We evaluated the effects of TAT-RH on 
tumor growth in BALB/c nude mice. High doses (16 mg/kg in 200 μl) lead to regression of tumors, intermediate doses (12 mg/
kg in 200 μl) are able to completely inhibit tumor growth and low doses (8 mg/kg in 200 μl) can only delay tumor growth. Fig-
ure also shows a representative image of tumors at the end of the treatment (inset). B) Tumors were homogenized and the 
biological effects of TAT-RH treatment were evaluated by WB. TAT-RH leads to a dose-dependent increase of IκBα and 
cleaved caspase 3 and a reduction of VEGF levels. TAT treated tumors were used as controls. C) To evaluate the effect of 
TAT-RH on NFκB activity, we performed an EMSA using nuclear extracts from tumors. TAT-RH treatment reduces NFκB 
activity. Lane 1 = probe alone; Lane 2 = empty; Lane 3-4 = TAT treated tumors; Lane 5-6 = TAT-RH treated tumors.Molecular Cancer 2009, 8:97 http://www.molecular-cancer.com/content/8/1/97
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blocks cell proliferation and consequently tumor growth
in a dose dependent manner.
A clear advantage of our strategy of inhibition of NFκB is
the fact that there is no overexpression of a transgene, but
rather, the pharmacological inhibition of a mechanism of
degradation of IκB which is both efficient and selective.
One concern about inhibiting the NFκB pathway is the
specificity. In particular, the proteasome which is respon-
sible for IκB degradation has many other important func-
tions. Thus, inhibition of proteasome activity could
potentially cause severe side effects [44]. Since our strategy
is based on the sterical interaction of TAT-RH and IκB and
therefore does not require the inhibition of a general cel-
lular mechanism, such as the proteasome, we hypothesize
that the side effects of chronic treatment with TAT-RH, or
a small molecule resembling it, will be of minimal inten-
sity. Indeed, TAT-RH protein is not toxic when delivered
through a systemic route, as it did not induce organ dam-
age in mice. Thus, our data suggest that TAT-RH protein is
a potent inhibitor of tumor growth both in vitro and in
vivo, that is safe and well tolerated when administered sys-
temically.
We believe that the anti-tumoral properties of GRK5-RH
rely at least on two possible mechanisms. It is well known
that apoptosis induced by chemotherapies is attenuated
in tumor cells showing enhanced NFκB activity [1,45-47].
Here we demonstrated that GRK5-RH is able to induce
apoptotic events in our model of cancer as evidenced by
increased levels of the active form of caspase 3 (both by
western blot and histological analysis) and Annexin V
staining. Another feature that characterizes aggressive
tumors is the ability to generate new vessels. Tumor ang-
iogenesis has shown to be dependent on angiogenic fac-
tors, like chemokines and growth factors produced by
macrophages, neutrophils and other inflammatory cells,
all factors that have been shown to be regulated by NFκB
[48,49]. GRK5-RH treatment reduces VEGF expression
and production compared to controls and inhibits angio-
genesis, thus providing another mechanism for retarding
the in vivo growth of KAT-4 cells.
Conclusion
This study demonstrates the ability of the RH domain of
GRK5 to inhibit tumor growth through NFκB antago-
nism. This effect is achieved both in vitro and in vivo either
through gene therapy or injection of TAT-RH protein.
Thus, our data propose GRK5-RH as an useful therapeutic
tool for cancer.
Histological analysis of TAT-RH treated tumors Figure 7
Histological analysis of TAT-RH treated tumors. Con-
trol and treated tumors were analized by histology. A) To 
evaluate angiogenesis in these tumors, lectin staining was 
used to visualize microvessels. TAT-RH reduces the forma-
tion of tumor vasculature. B and C) Cell death and prolifer-
ation were evaluated by analysis of cleaved caspase 3 and 
PCNA levels. TAT-RH treated tumors show increased 
cleaved caspase 3 levels (B) and reduced cell proliferation 
(C). D) We also evaluated IκBα subcellular localization. IκBα 
mainly localizes in the cytosol in control tumors while TAT-
RH treatment causes its nuclear accumulation.
Real-Time PCR analysis of inflammation and angiogenesis in  TAT-RH treated tumors Figure 8
Real-Time PCR analysis of inflammation and angio-
genesis in TAT-RH treated tumors. VEGF and TNFα 
expression was evaluated by Real Time PCR to assess the 
ability of TAT-RH to inhibit NFκB-dependent gene expres-
sion in cancer cells. At 2 weeks from starting treatment 
VEGF and TNFα expression is strongly inhibited in a dose 
dependent manner and prolonged treatments (4 weeks) 
increase such effect (*p < 0.05 vs control).Molecular Cancer 2009, 8:97 http://www.molecular-cancer.com/content/8/1/97
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